Aminex Launches Mid-Stage Trial of Polyamine-Targeting Therapy in Solid Tumors

Novel approach attacks production of polyamines that tumors require to proliferate and suppress the immune system  Aminex Therapeutics, Inc., a...

February 06, 2026 | Friday | News
Cellares Expands Automation Platform into Gene-Edited HSC Therapies Through Stanford Medicine Collaboration

Cellares, the first Integrated Development and Manufacturing Organization (IDMO), announced a collaboration with the Stanford Center for Definitive and C...

February 05, 2026 | Thursday | News
Promega Secures NMPA Approval for OncoMate® MSI Detection Kit as Companion Diagnostic for KEYTRUDA® in China

The National Medical Products Administration (NMPA) has approved the OncoMate® Microsatellite Instability (MSI) Detection Kit as a Class III in vitro...

February 05, 2026 | Thursday | News
Olympus EAGLE Trial Shows Cloud-Based AI Improves Detection of Clinically Significant Colorectal Lesions Without Disrupting Workflow

Cloud-based AI application for colorectal cancer prevention: Enhancing detection of clinically significant lesions without compromising safety and workfl...

February 05, 2026 | Thursday | News
SEQSTER and Praxis Expand Collaboration to Accelerate CNS Clinical Development

Multi-study collaboration leverages SEQSTER's real world data (RWD) platform to support Praxis's portfolio of precision therapies for CNS disorders ...

February 04, 2026 | Wednesday | News
MedImpact Expands Health Solutions Platform With Sav-Rx Acquisition

Transaction expands MedImpact’s scale, expertise, and health solutions portfolio while maintaining Sav-Rx’s mission and service model ...

February 03, 2026 | Tuesday | News
Imviva Biotech’s CTD402 Granted FDA Orphan Drug Designation for Relapsed/Refractory T-ALL/LBL

Imviva Biotech, a clinical-stage biotechnology company developing next-generation allogeneic CAR-T cell therapies, announced that the U.S. Food and Drug ...

January 29, 2026 | Thursday | News
Ernexa Therapeutics Selected for Japan Entry Acceleration Program, Joining Elite Group of Global Cell Therapy Innovators

Ernexa Therapeutics (Nasdaq: ERNA), an industry innovator developing novel cell therapies for the treatment of advanced cancer and autoimmune disease, to...

January 29, 2026 | Thursday | News
SK Capital to Divest Noramco API Assets to Siegfried as Halo Pharma Emerges as Stand-Alone Drug Product CDMO

SK Capital Partners have signed a definitive agreement to divest the Noramco API related assets in a sale to Siegfried (Zofingen Switzerland) The...

January 29, 2026 | Thursday | News
Boehringer Ingelheim’s Apecotrep Delivers 40% Proteinuria Reduction in Phase II Primary FSGS Trial

Apecotrep (BI 764198) is a potential first-in-class, oral, selective TRPC6 inhibitor being investigated as a novel, targeted, non-immunosuppressive the...

January 29, 2026 | Thursday | News
Japan’s J-TEC Secures National Insurance Reimbursement for JACC in Knee Osteoarthritis

-Japan Tissue Engineering Co., Ltd.(J-TEC) announced that JACC, its autologous cultured cartilage product, has been granted approval by Japan’s N...

January 28, 2026 | Wednesday | News
Argo Biopharma and Novartis Dose First Patient in Phase 2b Trial of siRNA Therapy BW-20829

Argo Biopharmaceutical Co., Ltd. (Argo Biopharma), a clinical-stage biotechnology company committed to developing next-generation siRNA therapies, announ...

January 27, 2026 | Tuesday | News
BioArctic Partner Eisai Secures FDA Priority Review for Subcutaneous Leqembi Iqlik

BioArctic AB's (publ) (STO: BIOA B) partner Eisai announced  that the supplemental Biologics License Application (sBLA) for Leqembi Iqlik subcutaneo...

January 27, 2026 | Tuesday | News
Eisai and Biogen’s LEQEMBI IQLIK Moves Toward First At-Home Anti-Amyloid Treatment for Alzheimer’s

If approved, LEQEMBI IQLIK would be the first and only anti-amyloid treatment to offer at-home injection options for initiation and maintenance dosing fo...

January 27, 2026 | Tuesday | News

Survey Box

Poll of the Week

Which area of biopharmaceutical research excites you the most?

× Please select an option to participate in the poll.
Processing...
× You have successfully cast your vote.
 {{ optionDetail.option }}  {{ optionDetail.percentage }}%
 {{ optionDetail.percentage }}% Complete
More polls
Stay Connected

Sign up to our free newsletter and get the latest news sent direct to your inbox

© 2026 Biopharma Boardroom. All Rights Reserved.

Show

Forgot your password?

Show

Show

Lost your password? Please enter your email address. You will receive a link to create a new password.

Back to log-in

Close